Equities

Chiome Bioscience Inc

4583:TYO

Chiome Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)111.00
  • Today's Change2.00 / 1.83%
  • Shares traded873.70k
  • 1 Year change-26.97%
  • Beta1.0892
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,3261,7271,791
Total Receivables, Net10814562
Total Inventory647159
Prepaid expenses131149305
Other current assets, total0.850.010.43
Total current assets1,6292,0922,217
Property, plant & equipment, net1.172.444.20
Goodwill, net------
Intangibles, net--00
Long term investments------
Note receivable - long term------
Other long term assets113113113
Total assets1,7512,2152,339
LIABILITIES
Accounts payable383230
Accrued expenses323344
Notes payable/short-term debt291184183
Current portion long-term debt/capital leases------
Other current liabilities, total178122135
Total current liabilities539370393
Total long term debt000
Total debt291184183
Deferred income tax------
Minority interest------
Other liabilities, total555454
Total liabilities594425446
SHAREHOLDERS EQUITY
Common stock2,3882,0971,516
Additional paid-in capital3,9883,6973,116
Retained earnings (accumulated deficit)(5219)(4003)(2738)
Treasury stock - common(0.29)(0.29)(0.29)
Unrealized gain (loss)------
Other equity, total0--0.00
Total equity1,1581,7911,893
Total liabilities & shareholders' equity1,7512,2152,339
Total common shares outstanding534841
Treasury shares - common primary issue0.010.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.